IDH1 and oligodendroglioma: IDH1/2 mutations have been estimated to occur in 54–100% of diffuse astrocytomas (WHO II), 66.1% of anaplastic astrocytomas (WHO III), and 64–93% of oligodendrogliomas (WHO II and III) cases [22].